Interstitial lung disease induced by Toripalimab combined with disitamab Vedotin in upper tract urothelial carcinoma: a case report and literature review
Abstract Background Upper tract urothelial carcinoma (UTUC) is a rare subtype of urothelial cancer, accounting for only 5–10% of cases, and is characterized by aggressive biological behavior. Recent advances in immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) have expanded the...
Saved in:
| Main Authors: | Peng Ding, Huanhuan Lin, Kaichen Zhang, Qian Yang, Peiyang Gao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12890-025-03838-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluating the efficacy and safety of bladder-sparing regimen with Disitamab Vedotin combined with Toripalimab and pelvic lymph node dissection in muscle-invasive bladder cancer patients: study protocol of a multicenter single-arm phase II trial
by: Tianhang Lan, et al.
Published: (2025-05-01) -
Severe cutaneous drug toxicity following disitamab vedotin treatment for metastatic gastric cancer: a case report
by: Zhao Luping, et al.
Published: (2025-01-01) -
Disitamab vedotin combined with pyrotinib as salvage treatment in Her-2-amplified treatment refractory metastatic colorectal cancer: a case report
by: Jianxin Chen, et al.
Published: (2025-02-01) -
TNF Signaling Pathway Is the Key Pathway Regulated by Disitamab Vedotin in Bladder Cancer Cells
by: Xingxing Tang, et al.
Published: (2025-05-01) -
Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan
by: Negar Pourjamal, et al.
Published: (2025-03-01)